{"hands_on_practices": [{"introduction": "Nuclear receptor function depends on recognizing specific DNA sequences, but this recognition involves more than just the half-site sequence. The precise geometry of the response element—specifically the spacing and orientation of binding sites—is crucial for determining which receptor dimers can bind. This practice explores the \"grammar\" of DNA response elements, demonstrating how the physical structure of DNA dictates binding specificity for different receptor heterodimers [@problem_id:2581742].", "problem": "A nuclear receptor heterodimer recognizes a direct repeat element composed of two half-sites with the consensus sequence $5^{\\prime}$-AGGTCA-$3^{\\prime}$ separated by a spacer of defined length (denoted DR$n$, where $n$ is the number of spacer base pairs). The DNA-binding domain (DBD) of nuclear receptors uses a recognition helix (the P-box) for half-site specificity and a dimerization interface (the D-box) to form inter-subunit contacts across adjacent half-sites. In canonical B-form deoxyribonucleic acid (DNA), the helical twist is approximately $34.3^\\circ$ per base pair with a helical repeat of approximately $10.5$ base pairs per turn, and the rise per base pair is approximately $3.4\\,\\mathrm{\\AA}$. These geometric constraints mean that changing the spacer length by $1$ base pair rotates the second half-site around the helical axis by roughly $34^\\circ$ relative to the first, altering the rotational registration of the two DBDs and the alignment of the D-box mediated dimer interface.\n\nTwo Retinoid X receptor (RXR) heterodimers, the Vitamin D receptor–Retinoid X receptor (VDR–RXR) and the Thyroid hormone receptor–Retinoid X receptor (TR–RXR), exhibit distinct spacing preferences for their response elements in vivo. Consider an enhancer that is changed from a DR$3$ to a DR$4$ configuration without altering the half-site sequences.\n\nWhich of the following best predicts how the binding affinities of VDR–RXR and TR–RXR will change upon this DR$3$ to DR$4$ spacer increase, and why, based on D-box mediated dimerization geometry and the rotational phasing imposed by B-DNA?\n\nA. VDR–RXR affinity will decrease, whereas TR–RXR affinity will increase, because adding $1$ base pair rotates the second half-site by approximately $34^\\circ$ to better match the TR–RXR D-box dimer geometry (optimal at DR$4$) while misaligning the VDR–RXR D-box interface (optimal at DR$3$).\n\nB. Both VDR–RXR and TR–RXR affinities will increase, because a larger spacer universally relieves steric clashes between DBDs regardless of D-box geometry.\n\nC. VDR–RXR affinity will increase, whereas TR–RXR affinity will decrease, because VDR–RXR requires a larger separation to allow its ligand-binding domains to recruit coactivators efficiently, independent of D-box geometry.\n\nD. Neither VDR–RXR nor TR–RXR affinity will change, because the D-box does not contact DNA and spacing preferences are set exclusively by ligand-binding domain interactions.\n\nE. Both VDR–RXR and TR–RXR affinities will decrease, because RXR heterodimers preferentially bind inverted repeats rather than direct repeats and thus are destabilized by any increase in spacer length.", "solution": "The problem statement must first be rigorously validated for its scientific and logical integrity.\n\n**Step 1: Extraction of Givens**\n- Core system: A nuclear receptor heterodimer.\n- DNA recognition site: A direct repeat (DR) element composed of two half-sites.\n- Half-site consensus sequence: $5^{\\prime}$-AGGTCA-$3^{\\prime}$.\n- Spacer definition: The two half-sites are separated by a spacer of $n$ base pairs, denoted DR$n$.\n- DNA-Binding Domain (DBD) components: A recognition helix (P-box) for half-site specificity and a dimerization interface (D-box) for inter-subunit contacts.\n- DNA properties: Canonical B-form DNA with a helical twist of approximately $34.3^\\circ$ per base pair, a helical repeat of approximately $10.5$ base pairs per turn, and a rise of approximately $3.4\\,\\mathrm{\\AA}$ per base pair.\n- Impact of spacer length: A change of $1$ base pair in the spacer rotates the second half-site by roughly $34^\\circ$, affecting the D-box mediated dimer interface.\n- Specific examples: Vitamin D receptor–Retinoid X receptor (VDR–RXR) and Thyroid hormone receptor–Retinoid X receptor (TR–RXR).\n- Known characteristic: These heterodimers have distinct spacing preferences for their response elements.\n- Experimental scenario: An enhancer's response element is changed from a DR$3$ configuration to a DR$4$ configuration.\n- Question: Predict the change in binding affinities for VDR–RXR and TR–RXR based on D-box geometry and rotational phasing.\n\n**Step 2: Validation of Problem Statement**\nThe problem is scientifically grounded. The description of nuclear receptor heterodimers, their DNA-binding domains (P-box and D-box), their recognition of direct repeat elements (DRs), and the influence of spacer length on binding geometry are all fundamental and accurate concepts in molecular biology and biochemistry. The specified values for B-form DNA geometry are standard textbook figures. The phenomenon of specific spacing preferences for different RXR heterodimers (the so-called \"3-4-5 rule\" for VDR, TR, and RAR, for example) is a well-established principle. The problem is well-posed, asking for a qualitative prediction based on a clearly defined biophysical model. The language is objective and precise. The problem is self-contained and presents no internal contradictions or factual errors. It addresses a core concept in transcriptional regulation and is not trivial or based on pseudoscience.\n\n**Step 3: Verdict**\nThe problem statement is valid. A definitive solution can be derived from established principles of molecular biology. I will now proceed with the derivation and evaluation of options.\n\n**Derivation of the Solution**\nThe interaction between a nuclear receptor dimer and its DNA response element is a highly specific, three-dimensional problem. The binding affinity is maximized when the geometry of the protein dimer interface is complementary to the spatial arrangement of the two DNA half-sites.\n\n$1$. The problem states that the DNA-binding domain (DBD) has a dimerization interface, the D-box, which mediates contacts between the two receptor monomers bound to adjacent half-sites. For stable binding, the D-boxes of the two monomers must be optimally positioned with respect to one another.\n\n$2$. The DNA linking the two half-sites is a helical polymer. The relative position and orientation of the second half-site depends on the length of the spacer. Increasing the spacer length by $1$ base pair increases the linear separation by approximately $3.4\\,\\mathrm{\\AA}$ and, crucially, rotates the second half-site by an angle of approximately $34.3^\\circ$ (stated as roughly $34^\\circ$) around the helical axis.\n\n$3$. Different nuclear receptor heterodimers have evolved distinct D-box interfaces, resulting in different optimal spacer lengths for maximal binding affinity. It is a canonical fact in this field that the VDR–RXR heterodimer exhibits maximal binding affinity to a DR$3$ element (a spacer of $3$ base pairs). In contrast, the TR–RXR heterodimer shows preferential binding to a DR$4$ element (a spacer of $4$ base pairs).\n\n$4$. The experimental change is from a DR$3$ element to a DR$4$ element.\n    - For the VDR–RXR heterodimer, the original DR$3$ element represents the optimal configuration. Changing the spacer to $4$ base pairs introduces a rotational and translational shift away from this optimum. This geometric misalignment weakens the protein-protein interactions at the D-box interface, destabilizing the complex. Consequently, the binding affinity of VDR–RXR for the DR$4$ element will be significantly lower than for the DR$3$ element.\n    - For the TR–RXR heterodimer, the optimal configuration is a DR$4$ element. The original DR$3$ element is a suboptimal binding site. By changing the spacer from $3$ to $4$ base pairs, the second half-site is moved into the position that allows for the most favorable D-box interactions for the TR–RXR dimer. This improved geometric complementarity strengthens the protein-protein interactions. Therefore, the binding affinity of TR–RXR for the DR$4$ element will be significantly higher than for the DR$3$ element.\n\n**Evaluation of Options**\n\n**A. VDR–RXR affinity will decrease, whereas TR–RXR affinity will increase, because adding $1$ base pair rotates the second half-site by approximately $34^\\circ$ to better match the TR–RXR D-box dimer geometry (optimal at DR$4$) while misaligning the VDR–RXR D-box interface (optimal at DR$3$).**\nThis option correctly predicts the direction of affinity change for both heterodimers. It correctly attributes this change to the specific, optimal spacing requirements of each dimer (DR$3$ for VDR–RXR, DR$4$ for TR–RXR) and the geometric consequences of altering the spacer length, which affects the alignment of the D-box dimerization interface. This reasoning is entirely consistent with the biophysical principles outlined in the problem and in established literature.\n**Verdict: Correct.**\n\n**B. Both VDR–RXR and TR–RXR affinities will increase, because a larger spacer universally relieves steric clashes between DBDs regardless of D-box geometry.**\nThis assertion is incorrect. It posits a universal, non-specific effect of increasing spacer length, which contradicts the central principle of specific, optimal geometries for dimerization. Binding affinity is not a monotonic function of spacer length; it is maximal at a specific length and decreases for both shorter and longer spacers. The affinity for VDR–RXR will decrease, not increase.\n**Verdict: Incorrect.**\n\n**C. VDR–RXR affinity will increase, whereas TR–RXR affinity will decrease, because VDR–RXR requires a larger separation to allow its ligand-binding domains to recruit coactivators efficiently, independent of D-box geometry.**\nThis option presents the incorrect direction of affinity changes for both dimers. Furthermore, it incorrectly claims the effect is independent of the D-box geometry, which is the primary determinant of spacing specificity for DNA binding. While ligand-binding domain (LBD) conformation is important for function, the initial high-affinity binding to DNA is dictated by the DBDs.\n**Verdict: Incorrect.**\n\n**D. Neither VDR–RXR nor TR–RXR affinity will change, because the D-box does not contact DNA and spacing preferences are set exclusively by ligand-binding domain interactions.**\nThis statement is factually flawed. The problem itself specifies that the D-box forms \"inter-subunit contacts across adjacent half-sites,\" and its alignment is critically dependent on the DNA spacer geometry. Therefore, the D-box is the key structural element determining the spacing preference at the level of the DBDs. Spacing preferences are not determined \"exclusively\" by LBDs.\n**Verdict: Incorrect.**\n\n**E. Both VDR–RXR and TR–RXR affinities will decrease, because RXR heterodimers preferentially bind inverted repeats rather than direct repeats and thus are destabilized by any increase in spacer length.**\nThis statement is based on a false premise. Type II nuclear receptors, which include the VDR–RXR and TR–RXR heterodimers, are defined by their preference for direct repeats (DRs), not a general preference for inverted repeats (which are characteristic of Type I steroid receptors). The entire basis of the option is factually wrong.\n**Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "2581742"}, {"introduction": "Having explored the structural rules of DNA recognition, we now turn to the architecture of the receptor protein itself. This exercise examines the powerful concept of domain modularity, where distinct protein regions carry out independent functions. By analyzing a hypothetical chimeric receptor, you will dissect how separate domains for DNA binding and ligand sensing integrate to produce a specific and predictable signaling outcome [@problem_id:2581763].", "problem": "A chimeric nuclear receptor is engineered by domain swapping to test how modular domains determine signaling specificity. The construct contains: the glucocorticoid receptor (GR; gene symbol *NR3C1*) N-terminal A/B region harboring Activation Function-$1$ (AF-$1$), the estrogen receptor alpha (ERα; gene symbol *ESR1*) DNA-binding domain (DBD) including the D-box, and the GR hinge plus ligand-binding domain (LBD) including Activation Function-$2$ (AF-$2$). The DBD of ER and GR each comprise two Cys$_2$-His$_2$ zinc fingers, and nuclear hormone receptors generally bind palindromic response elements as inverted repeats with IR-3 spacing. You transiently transfect this chimera into a mammalian cell line genetically null for endogenous ER and GR, together with either an estrogen response element (ERE)-driven luciferase reporter or a glucocorticoid response element (GRE)-driven luciferase reporter. After transfection, cells are treated with vehicle or dexamethasone at $100\\,\\text{nM}$ for $16\\,\\text{h}$.\n\nBased solely on fundamental definitions of nuclear receptor domain architecture, DNA recognition by zinc-finger DBDs, and ligand-dependent activation by LBDs (including AF-$2$-mediated coactivator recruitment), predict which class of response elements the chimera will occupy with high specificity in chromatin and whether dexamethasone will activate transcription from an ERE reporter in this system. Choose the single best answer and be prepared to justify the mechanistic basis in terms of domain function and dimerization geometry.\n\nOptions:\n\nA. The chimera binds EREs with high specificity and dexamethasone activates the ERE reporter, because the ER DBD dictates ERE recognition and the GR LBD confers dexamethasone-dependent AF-$2$ coactivator recruitment on DNA-bound dimers.\n\nB. The chimera binds GREs with high specificity and dexamethasone activates only the GRE reporter, because the GR LBD dictates DNA response element recognition in nuclear receptors.\n\nC. The chimera binds EREs with high specificity but dexamethasone does not activate the ERE reporter, because the GR LBD cannot productively recruit coactivators when the receptor is bound to an ERE through an ER DBD.\n\nD. The chimera binds neither EREs nor GREs with high specificity and dexamethasone fails to activate the ERE reporter, because mixing an ER DBD with a GR LBD disrupts dimerization geometry required for inverted repeat IR-3 elements.", "solution": "The problem statement must first be validated for scientific soundness, self-consistency, and clarity before a solution is attempted.\n\n### Step 1: Extract Givens\n-   **Chimeric Receptor Construct**:\n    -   N-terminal A/B region: From glucocorticoid receptor (GR; gene symbol *NR3C1*), containing Activation Function-$1$ (AF-$1$).\n    -   DNA-binding domain (DBD): From estrogen receptor alpha (ERα; gene symbol *ESR1*), containing two Cys$_2$-His$_2$ zinc fingers and a D-box.\n    -   Hinge plus Ligand-binding domain (LBD): From GR, containing Activation Function-$2$ (AF-$2$).\n-   **General Principles Stated**:\n    -   Nuclear hormone receptors (NHRs) generally bind palindromic response elements as inverted repeats with IR-3 spacing.\n-   **Experimental System**:\n    -   Cell Line: Mammalian, genetically null for endogenous ER and GR.\n    -   Transfected Plasmids:\n        1.  The chimeric receptor construct.\n        2.  Either an estrogen response element (ERE)-driven luciferase reporter or a glucocorticoid response element (GRE)-driven luciferase reporter.\n    -   Treatment: Vehicle (control) or dexamethasone at $100\\,\\text{nM}$ for $16\\,\\text{h}$.\n-   **Question**:\n    -   Predict which class of response elements the chimera will occupy with high specificity.\n    -   Predict whether dexamethasone will activate transcription from an ERE reporter.\n\n### Step 2: Validate Using Extracted Givens\n1.  **Scientifically Grounded**: The problem is well-grounded in the established principles of molecular endocrinology and gene regulation. The modular nature of nuclear hormone receptor domains (DBD, LBD, AF-$1$/AF-$2$) is a central concept. Domain-swapping experiments are a standard technique used to dissect protein function. Dexamethasone is a canonical synthetic glucocorticoid and GR agonist. The experimental setup (reporter assays in null cells) is classic and appropriate. The problem is scientifically sound.\n2.  **Well-Posed**: The problem is well-posed. The composition of the chimeric protein is explicitly defined. The experimental conditions are clear. The question asks for a specific prediction based on the provided information and fundamental principles. A unique, logical conclusion can be derived.\n3.  **Objective**: The language is precise, technical, and free of subjective or ambiguous terminology. It requires a prediction based on mechanistic understanding, not opinion.\n4.  **Incomplete or Contradictory Setup**: The problem is self-contained. It provides all necessary information about the protein domains, ligands, and DNA elements to make a reasoned prediction. There are no internal contradictions. The statement that NHRs *generally* bind IR-3 elements is a simplification, but one that holds true for the parent receptors in question (ER and GR), making it a consistent premise within the problem's context.\n5.  **Unrealistic or Infeasible**: The experiment described is entirely realistic and has been performed in various forms in research laboratories.\n6.  **Ill-Posed or Poorly Structured**: The problem is not ill-posed. It requires applying first principles of protein function to predict the behavior of a novel construct.\n7.  **Pseudo-Profound, Trivial, Tautological**: The problem is a non-trivial test of understanding domain function and modularity in signal transduction.\n8.  **Outside Scientific Verifiability**: The prediction is experimentally verifiable.\n\n### Step 3: Verdict and Action\nThe problem statement is valid. A solution will be derived based on the fundamental principles of nuclear receptor biology.\n\n### Derivation of Solution\nThe behavior of the chimeric receptor is determined by the distinct functions of its constituent domains. This is the principle of domain modularity.\n\n1.  **DNA-Binding Specificity**: The specificity of a nuclear receptor for its DNA response element is determined by the DNA-Binding Domain (DBD). The chimeric receptor contains the DBD from the estrogen receptor alpha (ERα). The ERα DBD recognizes the consensus sequence of an Estrogen Response Element (ERE), which is typically a palindromic inverted repeat of the $5^{\\prime}$-GGTCA-$3^{\\prime}$ half-site with a 3 base-pair spacer (IR-3). It does not recognize the consensus sequence of a Glucocorticoid Response Element (GRE), which has a different half-site sequence ($5^{\\prime}$-GGTACA-$3^{\\prime}$). Therefore, the chimeric receptor will bind with high specificity to EREs, not GREs.\n\n2.  **Ligand-Dependent Activation**: Ligand binding and subsequent ligand-dependent transcriptional activation (mediated by AF-$2$) are functions of the Ligand-Binding Domain (LBD). The chimeric receptor contains the LBD from the glucocorticoid receptor (GR). This LBD specifically binds glucocorticoids, such as dexamethasone. It does not bind estrogens. Upon binding dexamethasone, the GR LBD undergoes a conformational change that creates a binding surface for coactivator proteins. This surface is the Activation Function-$2$ (AF-$2$). The recruitment of these coactivators to the promoter is essential for initiating transcription.\n\n3.  **Synthesis of Function**:\n    -   The chimera, containing the ERα DBD, will localize to and occupy EREs within the cell, including the ERE on the co-transfected luciferase reporter plasmid.\n    -   Upon treatment with dexamethasone, the GR LBD portion of the chimera will bind the ligand.\n    -   Ligand binding will activate the AF-$2$ function of the GR LBD, leading to the recruitment of coactivators.\n    -   The complete complex—chimera bound to dexamethasone, coactivators, and the ERE—will then drive transcription of the downstream luciferase gene.\n    -   Consequently, treatment with dexamethasone should result in a significant increase in luciferase activity from the ERE-driven reporter. The GRE-driven reporter will not be activated because the chimera cannot bind to the GRE.\n\n### Evaluation of Options\n\n**A. The chimera binds EREs with high specificity and dexamethasone activates the ERE reporter, because the ER DBD dictates ERE recognition and the GR LBD confers dexamethasone-dependent AF-2 coactivator recruitment on DNA-bound dimers.**\n-   This statement correctly identifies that the ERα DBD determines binding to EREs.\n-   It correctly identifies that the GR LBD confers responsivity to dexamethasone, leading to AF-$2$-mediated activation.\n-   The reasoning correctly applies the principle of domain modularity to predict the outcome. The dimerization is assumed to be functional, which is reasonable given that both parent receptors bind IR-3 elements and have structurally related LBD dimerization interfaces.\n-   **Verdict: Correct.**\n\n**B. The chimera binds GREs with high specificity and dexamethasone activates only the GRE reporter, because the GR LBD dictates DNA response element recognition in nuclear receptors.**\n-   The premise that the LBD dictates DNA recognition is fundamentally incorrect. The DBD is responsible for this function. The chimera has an ERα DBD and will therefore bind EREs, not GREs.\n-   **Verdict: Incorrect.**\n\n**C. The chimera binds EREs with high specificity but dexamethasone does not activate the ERE reporter, because the GR LBD cannot productively recruit coactivators when the receptor is bound to an ERE through an ER DBD.**\n-   This option correctly identifies binding to EREs. However, it proposes a failure in transcriptional activation. This would require a negative allosteric effect, where the identity of the DNA element (ERE) prevents the LBD from functioning correctly. While complex allostery can exist in biological systems, the problem asks for a prediction based on *fundamental definitions* of modular domain function. The fundamental, first-order model assumes the domains operate independently. In this model, the dexamethasone-activated GR LBD should function to recruit coactivators regardless of the specific DNA sequence to which its DBD is tethered. Thus, this option contradicts the principle of modularity.\n-   **Verdict: Incorrect.**\n\n**D. The chimera binds neither EREs nor GREs with high specificity and dexamethasone fails to activate the ERE reporter, because mixing an ER DBD with a GR LBD disrupts dimerization geometry required for inverted repeat IR-3 elements.**\n-   This option suggests a catastrophic structural failure. While chimeras can sometimes misfold or fail to function, it is not the most parsimonious prediction. The LBDs of steroid receptors form the primary dimerization interface, and the GR LBDs in the chimera should form a stable dimer. The hinge region provides flexibility. Both EREs and GREs are IR-3 elements, so the required spacing is identical. It is far more likely that the flexible hinge allows the two ERα DBDs of the dimer to adopt the correct orientation to bind the ERE. A complete failure of binding is less plausible than the successful modular function described in option A.\n-   **Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "2581763"}, {"introduction": "This final practice bridges the gap between molecular binding events and the physiological response, translating the physical interaction of a ligand with its receptor into a quantitative measure of transcriptional activity. You will apply the law of mass action to relate ligand concentration to receptor occupancy. Furthermore, you will explore how a ligand's intrinsic ability to activate the receptor—its efficacy—ultimately determines the strength of the biological signal, distinguishing full from partial agonists [@problem_id:2581784].", "problem": "A ligand-activated nuclear hormone receptor is a transcription factor that binds small-molecule ligands in the nucleus and, upon ligand binding, recruits coactivators to modulate gene expression. Consider a single binding site per receptor with rapid equilibrium binding. The receptor and ligand interact via the reversible association reaction receptor plus ligand in equilibrium with receptor–ligand complex ($R + L \\rightleftharpoons RL$). The dissociation constant is defined by the ratio of free concentrations at equilibrium. The fractional occupancy is the fraction of total receptors that are ligand-bound. Assume that the free ligand concentration equals the applied concentration because the total receptor concentration is negligible relative to the total ligand.\n\nA receptor preparation exhibits a dissociation constant of $K_{d} = 5\\,\\mathrm{nM}$. You sequentially expose cells expressing this receptor to ligand concentrations of $1\\,\\mathrm{nM}$, $5\\,\\mathrm{nM}$, and $50\\,\\mathrm{nM}$, each for an equal duration, under conditions where the total receptor concentration remains constant and ligand depletion is negligible.\n\nThere are two ligands: ligand $A$ is a full agonist with intrinsic efficacy $\\varepsilon_{A} = 1$, and ligand $B$ is a partial agonist with intrinsic efficacy $\\varepsilon_{B} = 0.35$. Assume that, in this system, the steady-state transcriptional output is proportional to the product of intrinsic efficacy and fractional occupancy, and that there is no receptor reserve or cooperativity beyond a single binding event.\n\nTasks:\n1) Starting from the definition of the dissociation constant at equilibrium and the definition of fractional occupancy, derive an expression for the fractional occupancy as a function of free ligand concentration and $K_{d}$.\n2) Using your expression, compute the fractional occupancy at $1\\,\\mathrm{nM}$, $5\\,\\mathrm{nM}$, and $50\\,\\mathrm{nM}$.\n3) Using the proportionality between transcriptional output and the product of intrinsic efficacy and occupancy, compute the ratio of the time-averaged transcriptional output of ligand $B$ to that of ligand $A$ across the three equally long exposures.\n\nExpress the final ratio as a dimensionless number rounded to four significant figures.", "solution": "The problem as stated is scientifically grounded, self-contained, and well-posed. It presents a standard model of ligand-receptor binding and its effect on a downstream biological process. All necessary parameters and definitions for a unique solution are provided. We will proceed with the derivation and calculation.\n\nThe problem is divided into three tasks. We address them in sequence.\n\nTask 1: Derivation of the expression for fractional occupancy.\n\nLet $R$ denote the free receptor, $L$ the free ligand, and $RL$ the receptor-ligand complex. The reversible binding process is described by the equilibrium:\n$$\nR + L \\rightleftharpoons RL\n$$\nThe dissociation constant, $K_d$, is defined by the concentrations of the species at equilibrium:\n$$\nK_d = \\frac{[R][L]}{[RL]}\n$$\nThe total receptor concentration, $[R]_{\\text{total}}$, is the sum of the concentrations of free receptor and bound receptor:\n$$\n[R]_{\\text{total}} = [R] + [RL]\n$$\nThe fractional occupancy, which we denote by $Y$, is the fraction of the total receptor population that is bound to the ligand:\n$$\nY = \\frac{[RL]}{[R]_{\\text{total}}}\n$$\nTo derive an expression for $Y$ as a function of $[L]$ and $K_d$, we must express $[RL]$ and $[R]_{\\text{total}}$ in terms of these variables.\nFrom the definition of $K_d$, we can express the free receptor concentration $[R]$ as:\n$$\n[R] = \\frac{K_d [RL]}{[L]}\n$$\nSubstituting this expression for $[R]$ into the equation for $[R]_{\\text{total}}$ gives:\n$$\n[R]_{\\text{total}} = \\frac{K_d [RL]}{[L]} + [RL]\n$$\nFactoring out $[RL]$ on the right side yields:\n$$\n[R]_{\\text{total}} = [RL] \\left( \\frac{K_d}{[L]} + 1 \\right) = [RL] \\left( \\frac{K_d + [L]}{[L]} \\right)\n$$\nNow, we can substitute this expression for $[R]_{\\text{total}}$ into the definition of fractional occupancy $Y$:\n$$\nY = \\frac{[RL]}{[RL] \\left( \\frac{K_d + [L]}{[L]} \\right)}\n$$\nThe term $[RL]$ cancels from the numerator and denominator, leaving:\n$$\nY = \\frac{1}{\\frac{K_d + [L]}{[L]}} = \\frac{[L]}{K_d + [L]}\n$$\nThis is the well-known Hill-Langmuir equation for a single non-cooperative binding site. The problem states that the free ligand concentration $[L]$ can be approximated by the total applied ligand concentration, which we will also denote as $[L]$.\n\nTask 2: Computation of fractional occupancy at the specified ligand concentrations.\n\nThe given dissociation constant is $K_d = 5\\,\\mathrm{nM}$. We are to calculate the fractional occupancy $Y$ for three ligand concentrations: $[L_1] = 1\\,\\mathrm{nM}$, $[L_2] = 5\\,\\mathrm{nM}$, and $[L_3] = 50\\,\\mathrm{nM}$.\n\nFor $[L_1] = 1\\,\\mathrm{nM}$:\n$$\nY_1 = \\frac{[L_1]}{K_d + [L_1]} = \\frac{1}{5 + 1} = \\frac{1}{6}\n$$\nFor $[L_2] = 5\\,\\mathrm{nM}$:\n$$\nY_2 = \\frac{[L_2]}{K_d + [L_2]} = \\frac{5}{5 + 5} = \\frac{5}{10} = \\frac{1}{2}\n$$\nFor $[L_3] = 50\\,\\mathrm{nM}$:\n$$\nY_3 = \\frac{[L_3]}{K_d + [L_3]} = \\frac{50}{5 + 50} = \\frac{50}{55} = \\frac{10}{11}\n$$\nThese are the fractional occupancies at the three specified concentrations.\n\nTask 3: Computation of the ratio of time-averaged transcriptional outputs.\n\nThe problem states that the steady-state transcriptional output, which we shall call $O$, is proportional to the product of intrinsic efficacy, $\\varepsilon$, and fractional occupancy, $Y$. Let $k$ be the constant of proportionality.\n$$\nO = k \\cdot \\varepsilon \\cdot Y\n$$\nThe system is exposed to three different ligand concentrations for equal durations. Let this duration be $\\Delta t$. The total time of the experiment is $T_{\\text{total}} = 3\\Delta t$. The time-averaged transcriptional output, $\\bar{O}$, is the total output integrated over time, divided by the total time. Because the output is at a steady state for each concentration, the integral becomes a sum:\n$$\n\\bar{O} = \\frac{1}{T_{\\text{total}}} \\int_0^{T_{\\text{total}}} O(t) \\,dt = \\frac{1}{3\\Delta t} (O_1 \\Delta t + O_2 \\Delta t + O_3 \\Delta t) = \\frac{1}{3} (O_1 + O_2 + O_3)\n$$\nwhere $O_1$, $O_2$, and $O_3$ are the steady-state outputs at concentrations $[L_1]$, $[L_2]$, and $[L_3]$, respectively.\n\nFor ligand A, a full agonist, the intrinsic efficacy is $\\varepsilon_A = 1$. The time-averaged output is:\n$$\n\\bar{O}_A = \\frac{1}{3} (O_{A,1} + O_{A,2} + O_{A,3}) = \\frac{1}{3} (k \\varepsilon_A Y_1 + k \\varepsilon_A Y_2 + k \\varepsilon_A Y_3)\n$$\n$$\n\\bar{O}_A = \\frac{k \\varepsilon_A}{3} (Y_1 + Y_2 + Y_3)\n$$\nFor ligand B, a partial agonist, the intrinsic efficacy is $\\varepsilon_B = 0.35$. The time-averaged output is:\n$$\n\\bar{O}_B = \\frac{1}{3} (O_{B,1} + O_{B,2} + O_{B,3}) = \\frac{1}{3} (k \\varepsilon_B Y_1 + k \\varepsilon_B Y_2 + k \\varepsilon_B Y_3)\n$$\n$$\n\\bar{O}_B = \\frac{k \\varepsilon_B}{3} (Y_1 + Y_2 + Y_3)\n$$\nNote that the fractional occupancies $Y_1$, $Y_2$, and $Y_3$ are identical for both ligands, as they depend only on the ligand concentration and the receptor's $K_d$, which is the same in both scenarios.\n\nWe are asked to compute the ratio of the time-averaged transcriptional output of ligand B to that of ligand A.\n$$\n\\text{Ratio} = \\frac{\\bar{O}_B}{\\bar{O}_A} = \\frac{\\frac{k \\varepsilon_B}{3} (Y_1 + Y_2 + Y_3)}{\\frac{k \\varepsilon_A}{3} (Y_1 + Y_2 + Y_3)}\n$$\nThe terms $\\frac{k}{3}$ and $(Y_1 + Y_2 + Y_3)$ are common to both the numerator and the denominator and thus cancel out, provided that the sum of occupancies is not zero, which is true in this case.\nThe expression simplifies elegantly to the ratio of the intrinsic efficacies:\n$$\n\\text{Ratio} = \\frac{\\varepsilon_B}{\\varepsilon_A}\n$$\nSubstituting the given values $\\varepsilon_A = 1$ and $\\varepsilon_B = 0.35$:\n$$\n\\text{Ratio} = \\frac{0.35}{1} = 0.35\n$$\nThe problem requires the final answer to be rounded to four significant figures. Therefore, the ratio is $0.3500$.", "answer": "$$\n\\boxed{0.3500}\n$$", "id": "2581784"}]}